title: Characterization of human prostate and breast cancer cell lines for experimental T cell-based immunotherapy.
abstract: BACKGROUND
  In order to develop experimental immunotherapy for prostate and breast cancer it is of outmost importance to have representative target cell lines that through human leukocyte antigen (HLA) class I molecules present relevant levels of peptides from tumor-associated antigens for cytotoxic T lymphocyte (CTL) recognition.
  
  
  METHODS
  We sequenced the HLA-A and HLA-B loci of eight commonly used prostate and breast cancer cell lines and analyzed the surface expression of HLA-ABC, HLA-DR, CD40, CD80, CD86, and CD54 by flow cytometry. We also analyzed the cell lines for mRNA expression from 25 genes reported to be specifically or preferentially expressed by prostate cells.
  
  
  RESULTS
  Among the analyzed cell lines we found that LNCaP, PC-346C and MCF-7 are HLA-A*0201 positive. However, the HLA-A2 expression level is low and only MCF-7 upregulates HLA-A2 in response to IFN-gamma stimulation. MCF-7 also expresses high levels of CD54, which further improve its value as a CTL target cell line. On the other hand, LNCaP and PC-346C express 25 and 23 out of 25 prostate-related genes, respectively, while MCF-7 expresses 16 out of 25 genes.
  
  
  CONCLUSIONS
  None of the analyzed prostate cancer cell lines are optimal CTL target cells. However, MCF-7 could in many cases be used as a complement to HLA-A*0201 positive prostate cancer cells. The LNCaP and PC-346C cell lines are rich sources of prostate-related antigens that may be valuable for cancer vaccine development.
authors.affiliation: Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.
authors.forename: Björn
authors.initials: B
authors.lastname: Carlsson
authors.forename: Ole
authors.initials: O
authors.lastname: Forsberg
authors.forename: Mats
authors.initials: M
authors.lastname: Bengtsson
authors.forename: Thomas H
authors.initials: TH
authors.lastname: Tötterman
authors.forename: Magnus
authors.initials: M
authors.lastname: Essand
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology / Q000628:therapy*; D018122:B7-1 Antigen / Q000235:genetics; D051940:B7-2 Antigen / Q000235:genetics; D001943:Breast Neoplasms / Q000276:immunology / Q000628:therapy*; D019013:CD40 Antigens / Q000235:genetics; D002461:Cell Line, Transformed; D045744:Cell Line, Tumor; D015870:Gene Expression / Q000276:immunology; D015234:HLA-A Antigens / Q000235:genetics; D015235:HLA-B Antigens / Q000235:genetics; D015236:HLA-C Antigens / Q000235:genetics; D006684:HLA-DR Antigens / Q000235:genetics; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D018799:Intercellular Adhesion Molecule-1 / Q000235:genetics; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy*; D012333:RNA, Messenger; D013601:T-Lymphocytes / Q000502:physiology*
chemical_list: D018122:B7-1 Antigen; D051940:B7-2 Antigen; D019013:CD40 Antigens; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D015236:HLA-C Antigens; D006684:HLA-DR Antigens; D012333:RNA, Messenger; D018799:Intercellular Adhesion Molecule-1